UKIPO rejects Novartis’s TM opposition attempt

Switzerland-based Novartis has failed to convince the UK Intellectual Property Office (IPO) that a trademark applied-for by Boston Healthcare should not be registered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

27 March 2020 A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More features

President Trump 2.0: Five major areas to watch

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

UKIPO rejects Novartis’s TM opposition attempt

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features